Comments on Medicare ‘Negotiation’ Help Illuminate Policy Priorities

How Poor Launch-Price Disclosure Creates Both Immediate and Long-Term Risks

Plus a look at how MFN is impacting drug launches in Canada

The Government’s Gauge of Inflation Says Drug Prices Are Plummeting. Does That Mean Anything?

Plus important context around data suggesting employers are fleeing the “Big Three” PBMs

Looking Deeper: 1H26 Launch Prices and the Tragedy of the Commons

Why We Shouldn’t Expect the SXSW Crowd to Solve American Healthcare

GoodRx Disclosures and Web Traffic Stats Suggest TrumpRx Isn’t Making Much of a Difference

Another Summer Friday Top 10: CVS’ 340B ‘Headwinds,’ MFN Rebervations in Europe, Patient Burdens Under the IRA, and More

New 340B Legislation Would Leave Some of the Program’s More Controversial Elements Untouched

And Lilly and Novo weigh in on the early days of CMS’ Bridge program

2026 Launch Price Disclosures Are Looking Anemic

And four studies examining everything from 340B to orphan drug incentives

MFN Commentary Has Been Light During Earnings Season. Here Are Two Exceptions.

The Government Is Trying -- Again -- to Change the Way That Drugmakers Pay 340B Discounts

And are there hints that the Bridge program is boosting GLP-1 scripts?

CBO Details How the IRA’s Medicare Provisions May End Up Expanding the Deficit Instead of Saving Money

And the latest lawsuit pushing back on a new Lilly 340B is a great example of “safety-net cosplay”

Earnings Season Is In Full Swing, Which Could Shed Light on Where Companies Stand on MFN

Reuters Explores the Launch of CMS' Bridge Program, and Other Summer-Friday Highlights

It's a short Curve in hopes that you're enjoying a long weekend

Everyone Agrees: Trump’s Threatened Tariffs on Generic Drugs Are Going to Hike Prices and Create Shortages

And no one really thinks the tariff proposal is likely to achieve the goal of onshoring manufacturing, either

Drugmakers Lose a Battle -- But Make Progress in the War -- Over 340B Rebate Models

Plus Trump pledges 100% tariffs on generic meds ... but the tariffs wouldn’t kick in until his term is nearly over

The Media Strategy Behind a New Novo Lawsuit, J&J Weighs in on 340B, and a Deep Dive on the Biggest – But Most Invisible – Companies in Healthcare

Activity Around CMS’ GENEROUS and GUARD Models Is a Reminder That MFN Policy Never Takes a Vacation

Why Hospitals Escape Responsibility for Rising Health Costs, and Nine Other Stories for a Summer Friday

The Implications of Merck’s Move to Price Its Cholesterol Pill at $315 a Month

And UnitedHealth Group’s revenues topped $100 billion -- again -- last quarter

CVS Caremark Settles Its FTC Insulin Lawsuit, Pledging Changes to the PBM Business Model

The 340B Program Topped $100 Billion in Annual Sales Last Year; Big Hospitals Continue to Dominate

Plus TrumpRx’s June site visits sunk to their lowest level since the site launched in February

A Spate of Articles on GLP-1 Value and Reimbursement Drive Home a Frustrating Reality

“This is the first time that we’ve seen significant restrictions on access to drugs that are safe and effective.”

Nearly a Third of Prescriptions Are Rejected by Insurers, and the Problem Is Getting Worse, JAMA Analysis Finds

Today’s Top 10: The Latest on Efforts to Break Up Insurance Companies, a Passel of 340B Links, and Solutions to Cell and Gene Therapy Coverage Dilemmas